Newsquawk Logo

Eli Lilly's (LLY) Retevmo delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

Eli Lilly's Retevmo showing a substantial event-free survival benefit in early-stage RET fusion-positive lung cancer is a significant advancement for their pipeline and can positively impact their revenue outlook in the oncology segment.

Newsquawk StaffPublished On the live feed at — 1 more headline followed before this page went public
Newsquawk headlinesUTC

The EU and a 12-nation Indo-Pacific bloc are opening talks to explore forming one of the largest global economic alliances, according to sources cited by POLITICO

Chevron (CVX) awarded four offshore leases for Greece exploration blocks

Eli Lilly's (LLY) Retevmo delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer

Russian delegation in Geneva to be expanded to about 20 people, according to reports

India's Trade Secretary says they're aiming to operationalise trade agreement with the UK by April

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

Market perception may be particularly bullish, as successful clinical data often translates into stronger stock performance and potential competitive positioning against peers in the pharmaceutical sector. Given the broader focus on innovative therapies, this could also enhance investor sentiment around biotech equities in general.

External

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.